New drug shows promise in shrinking lung tumors before surgery

NCT ID NCT05714891

Ongoing Disease control Sponsor: Canadian Cancer Trials Group Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests the drug JDQ443 in people with non-small cell lung cancer before they have surgery. The goal is to see if the drug can shrink tumors and improve outcomes. Only 4 participants are enrolled, so results are very early.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JDQ443
What this could lead to: If successful, this could identify a new treatment option to shrink lung cancer tumors before surgery, potentially improving outcomes.
What could go wrong: This is a very early, small trial with only 4 participants. The drug may not work as hoped, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC

Contacts and locations

Locations

CHUM-Centre Hospitalier de l'Universite de Montreal

Montreal, Quebec, H2X 3E4, Canada
CancerCare Manitoba

Winnipeg, Manitoba, R3E 0V9, Canada
Kingston Health Sciences Centre

Kingston, Ontario, K7L 2V7, Canada
London Health Sciences Centre Research Inc.

London, Ontario, N6A 5W9, Canada
Ottawa Hospital Research Institute

Ottawa, Ontario, K1H 8L6, Canada
The Research Institute of the McGill University

Montreal, Quebec, H4A 3J1, Canada
University Health Network

Toronto, Ontario, M5G 2M9, Canada
University Institute of Cardiology and

Québec, Quebec, G1V 4G5, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.